Life Sciences Angels Group

www.lifescienceangels.com

VCMatch tracks Life Sciences Angels Group as an investor focused on Biotech, Medtech, and Digital Health companies, Pre-Seed and Seed rounds, United States, San Francisco Bay Area (Preference), and Us Nationwide markets, and $100k to $1.1m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$100k to $1.1m

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Medtech, Digital Health

Geography

United States, San Francisco Bay Area (preference), and US-nationwide

Investment Thesis

Life Science Angels (LSA) is an early-stage, sector-focused angel group that invests exclusively in life sciences. They position themselves as “risk takers as early investors,” often providing the first institutional capital after grants and friends-and-family, and they emphasize active, hands-on support (board members/observers, mentoring, follow-on participation). Their process is rigorous and staged (pre-screen, screening, due diligence, invest, post-investment monitoring) and they seek disruptive technologies across the full spectrum of healthcare discovery and delivery with clear evidence of scientific/proof-of-concept and a path to liquidity within a multi-year horizon.

Is Life Sciences Angels Group right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Life Sciences Angels Group is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, Digital Health, and Pharma, especially across United States, San Francisco Bay Area (preference), and US-nationwide, with public check-size signals around $100k to $1.1m.

Focus statement

LSA invests exclusively in early-stage life science companies (Biotech/Therapeutics, Diagnostics, Digital Health, Drug Discovery, HealthTech, Medical Devices, Genomics, tools and related AI/new business models), preferring disruptive advances and companies structured as U.S. C‑Corporations with U.S.-controlled IP. They typically act as the first money in after grants/F&F and look for deals with significant return potential (generally 15X+).

Value Add

Sector exclusivity: “Investing in Life Sciences, Exclusively.”
Not-for-profit structure and fee model: "We take no carry or management fees on investments. We do not charge companies any fees."
Syndication / single-investor footprint: "We write one check for each investment and sign one set of paperwork so we appear as a single investor on the portfolio company capitalization tables."
Active involvement: "We prefer to be active investors and provide a board member or observer, or some other form of strategic or operational advisor."
Rigorous, multi-stage process with heavy member participation (pre-screen, bi-weekly screening, due diligence teams, deal lead and executive director coordination).
US legal/IP constraints: only considers companies "Incorporated as a U.S. C-Corporation" with "Intellectual property is controlled by the U.S. entity."
Member-driven investing via pooled LLCs (single paperwork/K-1s) with minimums and voting-by-checkbook decisioning (requires 6+ members for first-time investments).
Heavy emphasis on local investor validation for out-of-area deals: they will invest outside their geographic area but “prefer to see those companies supported by a local angel group.”